
    
      This will be an open-label, Phase 2A, multiple ascending dose study in 1 to 3 sites, designed
      to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple
      subcutaneous injections of 60mg, 90mg, and 120mg doses of risperidone in the RBP-7000
      formulation, in subjects with clinically-stable schizophrenia who are on a once daily stable
      dose of 2mg, 3mg, or 4mg of oral risperidone.
    
  